Drugs / Intravenous Immunoglobulin (IVIg)
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 2 | NCT05701189 Comparator | Sep 2024 → Jan 2026 | Guillain-Barre syndrome | Chafic Karam | Withdrawn | No outcome recorded Stop: Enrollment |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Intravenous Immunoglobulin (IVIg) | “Intravenous Immunoglobulin (IVIg)” NCT05701189 ↗ |
| Known as | IVIg | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05701189 ↗ |
| Modality | Protein / enzyme biologic | “Intravenous Immunoglobulin (IVIg)” NCT05701189 ↗ |
| Route | Intravenous | “0.4g/kg of IVIg daily for 5 days” NCT05701189 ↗ |